Effects of isolated limb perfusion with tumor necrosis factor-alpha on circulating levels of proinflammatory cytokines.
Hyperthermic isolated limb perfusion (ILP) with tumor necrosis factor-a (TNFalpha) and cytotoxic drugs is currently used for treatment of melanoma and sarcoma of the limbs. Tumor necrosis factor-alpha is involved in the systemic inflammatory response syndrome as a result of activation of inflammatory cells and production of bioactive substances. The goal of this study was to determine the circulating levels of proinflammatory cytokines and soluble adhesion molecules in 19 patients with limb melanoma or sarcoma undergoing ILP with (n = 9) or without TNFalpha (n = 10). The results obtained demonstrated that ILP with TNFalpha was responsible for a leakage of TNFalpha in the systemic circulation, followed by a rise in interleukin (IL)-6 and IL-8 levels within I h. Elevated soluble (s)P-selectin levels were found 1-3 h after ILP. Plasma sE-selectin peaked 6-9 h after ILP, and soluble vascular cell adhesion molecule (sVCAM) levels reached a maximum after 24 h. Significant correlations were observed among these variables, confirming the interdependence of all changes observed. On the other hand, ILP with cytotoxic drugs alone induced only a modest release of TNFalpha, which was not followed by an immediate rise in IL-6 and IL-8. Four of the 9 patients undergoing ILP with TNF had severe systemic toxicity. No association was found between systemic TNF levels and the clinical outcome, whereas elevated TNF perfusion levels as well as systemic IL-6 and IL-8 levels were constantly elevated in patients with severe toxicity. These results are suggestive of an important role of TNFalpha levels in the perfusion system (more than leakage of perfusate) in causing postoperative toxicity, although other ILP-related factors should not be excluded.
Ferroni
P
P
Department of Experimental Medicine and Pathology, University of Rome La Sapienza, Italy. patrizia.ferroni@uniromal.it
Di Filippo
F
F
Martini
F
F
Spila
A
A
D'Alessandro
T
T
Cavaliere
F
F
Anzà
M
M
Garinei
R
R
Aloe
S
S
Carone
M D
MD
Gazzaniga
P P
PP
Guadagni
F
F
D000328:Adult; D000368:Aged; D001777:Blood Coagulation / Q000502:physiology; D010478:Chemotherapy, Cancer, Regional Perfusion; D016207:Cytokines / Q000097:blood*; D005121:Extremities; D005260:Female; D006801:Humans; D007249:Inflammation / Q000139:chemically induced; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D012509:Sarcoma / Q000628:therapy; D019087:Selectins / Q000097:blood*; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000009:adverse effects* / Q000032:analysis; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood
D016207:Cytokines; D019087:Selectins; D014409:Tumor Necrosis Factor-alpha; D019010:Vascular Cell Adhesion Molecule-1